Trial Profile
Dose finding phase IIb study of Bavisant to evaluate its safety and efficacy in treatment of excessive daytime sleepiness (EDS) in parkinson's Disease (PD)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Nov 2020
Price :
$35
*
At a glance
- Drugs Bavisant (Primary)
- Indications Hypersomnia
- Focus Therapeutic Use
- Acronyms CASPAR
- Sponsors BenevolentAI
- 09 Jul 2019 Status changed from recruiting to completed.
- 21 Jun 2019 This trial has been completed in Czech Republic.
- 15 Jun 2019 This trial has been completed in Germany, according to European Clinical Trials Database.